L&G Global Health & Pharmaceuticals Index Trust R Acc
| Shares Class | Inc. |
|---|---|
| Yield | 0.90 |
| Total Expense Ratio | 0.00 |
Fund Performance
Cumulative Performance
Discrete Performance
| Shares Class | Inc. |
|---|---|
| Yield | 0.90 |
| Total Expense Ratio | 0.00 |
Cumulative Performance
Discrete Performance
| Fund Size | 655,755,955.00 | Launch Date | 01/11/2000 | Standard Initial Charge (%) | 0.00 |
|---|---|---|---|---|---|
| Currency | GBX | ISA Eligible | Yes | Annual Management Charge (%) | 0.00 |
| Sector | IMA UK Equity Income | Min Investment (£) | 100.00 | Total Expense Ratio (%) | 0.00 |
| ISIN | GB0001955532 | Min Topup (£) | 100.00 | Ongoing Charge (%) | 0.6900 (on 07/01/2020) |
The objective of this fund is to provide growth by tracking the performance of those companies in the FTSE World Index which are engaged in Health, Pharmaceuticals and Biotechnology activities.The fund will invest almost entirely in company shares. The fund's investments will closely match those that make up the Index. The Index consists of company shares from around the world.The fund may use derivatives (contracts which have a value linked to the price of another asset) for the following purposes:•To help with efficient day to day management.•To reduce some of the risks of the market.If you hold accumulation units, income from investments held by the fund (dividends) will be reinvested into the value of your units.If you hold distribution units, income from investments held by the fund will be paid out to you (as a dividend).This fund may not be appropriate for investors who plan to withdraw their money within five years.
Index Fund Management Team
The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.
| Name | Weight |
|---|---|
| Australian Equities | 2.00% |
| Danish Equities | 3.00% |
| French Equities | 2.00% |
| German Equities | 2.00% |
| International Equities | 3.00% |
| Japanese Equities | 7.00% |
| South Korean Equities | 1.00% |
| Swiss Equities | 8.00% |
| UK Equities | 4.00% |
| US Equities | 64.00% |
| Name | Weight |
|---|---|
| Australia | 2.00% |
| Denmark | 3.00% |
| France | 2.00% |
| Germany | 2.00% |
| Japan | 7.00% |
| Korea | 1.00% |
| Others | 3.00% |
| Switzerland | 8.00% |
| UK | 4.00% |
| USA | 64.00% |
| Name | Weight |
|---|---|
| JOHNSON & JOHNSON | 6.00% |
| UNITEDHEALTH GROUP INC | 5.00% |
| MERCK & CO INC(NEW) | 3.00% |
| NOVARTIS AG | 3.00% |
| PFIZER INC | 3.00% |
| ROCHE HLDG AG | 3.00% |
| ABBOTT LABORATORIES | 2.00% |
| ABBVIE INC | 2.00% |
| MEDTRONIC INC | 2.00% |
| THERMO FISHER SCIENTIFIC INC | 2.00% |
Please remember that past performance is not a guide of future returns. The value of investments and the income from them can go down as well as up as a result of currency exchange and market fluctuations and investors may not get back the amount originally invested.